<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605549</url>
  </required_header>
  <id_info>
    <org_study_id>CIN-107-122</org_study_id>
    <nct_id>NCT04605549</nct_id>
  </id_info>
  <brief_title>A Study of CIN-107 in Adults With Primary Aldosteronism</brief_title>
  <acronym>spark-PA</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of CIN-107 for the Treatment of Patients With Primary Aldosteronism (PA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CinCor Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CinCor Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, placebo-controlled, multicenter, parallel-group, dose-ranging&#xD;
      study in patients with PA to evaluate the efficacy and safety of up to 3 doses of CIN-107 as&#xD;
      compared to placebo after 4 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">March 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean seated systolic blood pressure (SBP)</measure>
    <time_frame>4 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean diastolic blood pressure (DBP)</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients achieving a seated BP response &lt;140/90 mmHg</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients achieving a seated BP response &lt;130/80 mmHg</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients achieving either a plasma aldosterone concentration (PAC &lt;15 ng/dL and a plasma renin activity (PRA) &gt;=0.5 ng/mL/hr; or an aldosterone-to-renin ratio (ARR) &lt;30.</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Primary Aldosteronism</condition>
  <condition>Hyperaldosteronism</condition>
  <arm_group>
    <arm_group_label>CIN-107 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CIN-107 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CIN-107 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for CIN-107</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIN-107 Dose 1</intervention_name>
    <description>CIN-107 tablets by mouth once daily</description>
    <arm_group_label>CIN-107 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIN-107 Dose 2</intervention_name>
    <description>CIN-107 tablets by mouth once daily</description>
    <arm_group_label>CIN-107 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIN-107 Dose 3</intervention_name>
    <description>CIN-107 tablets by mouth once daily</description>
    <arm_group_label>CIN-107 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for CIN-107</intervention_name>
    <description>Placebo for CIN-107 tablets by mouth once daily</description>
    <arm_group_label>Placebo for CIN-107</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18 years of age or older) with a diagnosis or suspected diagnosis of PA;&#xD;
&#xD;
          -  Is able to wash out of protocol-specified antihypertensive medication(s) for up to 4&#xD;
             weeks and remain washed out for the duration of the study treatment period; and&#xD;
&#xD;
          -  Is willing to take allowed, protocol-specified medication(s), if needed, to maintain&#xD;
             BP within protocol parameters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg;&#xD;
&#xD;
          -  Has a BMI &gt;40 kg/m2 and an arm circumference &lt;7 and &gt;17 inches;&#xD;
&#xD;
          -  Has had a previous surgical intervention or has a planned surgical intervention for an&#xD;
             adrenal adenoma or adrenal carcinoma, adrenalectomy, renal nerve denervation, or&#xD;
             adrenal ablative procedure during the course of the study;&#xD;
&#xD;
          -  Has a documented estimated glomerular filtration rate &lt;45 mL/min/1.73m2;&#xD;
&#xD;
          -  Has a planned dialysis or kidney transplantation during the course of the study;&#xD;
&#xD;
          -  Has known documented chronic heart failure;&#xD;
&#xD;
          -  Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute&#xD;
             coronary syndrome, or hospitalization for heart failure within 6 months before the&#xD;
             Screening Visit;&#xD;
&#xD;
          -  Has known current severe left ventricular outflow obstruction, such as obstructive&#xD;
             hypertrophic cardiomyopathy and/or severe aortic valvular disease, diagnosed from a&#xD;
             prior echocardiogram;&#xD;
&#xD;
          -  Has a planned or has had within 6 months of the Screening Visit a coronary&#xD;
             revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass&#xD;
             graft [CABG]) or any major surgical procedure during the study;&#xD;
&#xD;
          -  Has chronic permanent atrial fibrillation;&#xD;
&#xD;
          -  Plans to be on night shifts during the course of the study;&#xD;
&#xD;
          -  Has typical consumption of &gt;14 alcoholic drinks weekly;&#xD;
&#xD;
          -  Potassium &lt;2.5 mEq/L; and,&#xD;
&#xD;
          -  Potassium &gt;5.0 mEq/L.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brendan Doran, PharmD</last_name>
    <phone>513-579-9911</phone>
    <phone_ext>11242</phone_ext>
    <email>bdoran@cincor.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CinCor Site 07</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 08</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 05</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 16</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 03</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 10</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 14</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 12</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 18</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 04</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 02</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 01</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 11</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 15</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 09</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 17</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CinCor Site 06</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Aldosteronism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

